In sorafenib−resistant Huf7−SR cells, USP2 inhibition reduces cFILP expression, induces apoptosis, and enhances sorafenib sensitivity (283), whereas USP2 overexpression in renal carcinoma cells (A498 and CAKi−1) suppresses proliferation, migration, and invasion (284).Therapeutically, USP2 is an attractive target; ML364 is the most extensively studied USP2 inhibitor, with other inhibitors like Q29, STD1T, and LCAHA under investigation (285). Here, USP2 is linked to renal carcinoma.